静脉注射丙种球蛋白治疗新生儿ABO溶血病对血糖的影响——两种测定方法比较研究

目的:探讨静脉注射丙种球蛋白(IVIG)治疗新生儿ABO溶血病对血糖的影响。方法:选取我院2012年2月至2016年2月足月新生儿明确诊断为ABO溶血病33例并给予静脉注射IVIG的患儿为研究组,其中输注IVIG后血糖正常的14例患儿为研究1组,输注IVIG后血糖增高的19例患儿为研究2组;选择同期ABO溶血病未使用IVIG的34例患儿作为对照组。比较三组患儿治疗过程中的血糖变化情况。结果:研究1组用试纸法和葡萄糖氧化酶法监测输注IVIG后2 h血糖为(5.7±0.6)mmol/L和(5.7±0.5)mmol/L,输注后4 h的血糖为(5.7±0.9)mmol/L和(5.8±0.4)mmol/L(P均>0.05);研究2组用试纸法和葡萄糖氧化酶法监测输注IVIG后2 h后血糖为(11.7±0.6)mmol/L和(7.5±0.6)mmol/L,输注后4 h血糖为(12.5±0.8)mmol/L和(8.7±0.5)mmol/L(P均<0.05);对照组在相同时间点的血糖分别为(5.5±0.4)mmol/L和(5.9±0.4)mmol/L、(5.4±0.6)mmol/L和(5.3±0.3)mmol/L(P均>0.05)。结论:新生儿ABO溶血病患儿静脉输注IVIG过程中出现部分病例血糖增高,临床输注IVIG过程中应重视血糖检测,密切检测血糖情况,以减少高血糖对小儿产生危害。

Intravenous Injection Immunoglobulin in the Treatment of Neonatal ABO Hemolytic and Its Effect on Blood Glucose

Objective: To investigate intravenous injection immunoglobulin (IVIG) in the treatment of neonatal ABO hemolytic, and its effect on blood glucose. Methods: There were 33 cases of neonatal ABO hemolytic disease who were given intravenous injection immunoglobulin (IVIG) in our hospital from February 2012 to February 2016. Fourteen cases with normal blood glucose after treatment were selected as research group 1, 19 cases with increase blood glucose were selected as research group 2, and 34 cases of other newborns with ABO hemolytic disease with no IVIG as the control group. The blood glucose changes in three groups were compared. Results: After 2 hours of injection, the monitoring blood glucose of research group 1 were (5.7±0.6) mmol/L and (5.7±0.5) mmol/L, while 4 hours later were (5.7±0.9) mmol/L and (5.8±0.4) mmol/L (P<0.05). The monitoring blood glucose of group 2 were (11.7±0.6) mmol/L and (7.5±0.6) mmol/L, (12.5±0.8) mmol/L and (8.7±0.5) mmol/L(P<0.05). As for the control group, they were (5.5±0.4) mmol/L and (5.9±0.4) mmol/L, (5.4±0.6) mmol/L and (5.3±0.3) mmol/L(P<0.05). Conclusion: Neonatal ABO hemolytic disease treat with IVIG occurs in some cases of increased blood glucose, in the process of clinical infusion of IVIG, blood glucose detection should be paid attention to, close follow-up of blood glucose levels in order to reduce the risk of high blood glucose of neonates.